Browsing ODA Open Digital Archive by Author "Medhus, Asle Wilhelm"

Now showing items 1-7 of 7

    • Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort 

      Strande, Vibeke; Lund, Charlotte; Hagen, Milada; Bengtson, May-Bente; Boyar Cetinkaya, Raziye; Detlie, Trond Espen; Frigstad, Svein Oskar; Høie, Ole Ingebreth; Medhus, Asle Wilhelm; Henriksen, Magne; Holten, Kristina Ingeborg; Hovde, Øistein; Huppertz-Hauss, Gert; Johansen, Ingunn; Olsen, Bjørn Christian Elias Grova; Opheim, Randi; Ricanek, Petr; Torp, Roald; Tønnessen, Tor; Vatn, Simen Svendsen; Aabrekk, Tone Bergene; Høivik, Marte Lie; Kristensen, Vendel Ailin (Peer reviewed; Journal article, 2024)
      Background: The introduction of biologic therapies and the 'treat-to-target' treatment strategy may have changed the disease course of ulcerative colitis (UC). Aims: To describe the early disease course and disease outcome ...

    • Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study 

      Zerouga, Insaf; Valeur, Jørgen; Sommer, Christine; Småstuen, Milada Cvancarova; Medhus, Asle Wilhelm; Lund, Charlotte; Johansen, Ingunn; Boyar Cetinkaya, Raziye; Bengtson, May-Bente; Torp, Roald; Hovde, Øistein; Huppertz-Hauss, Gert; Detlie, Trond Espen; Aabrekk, Tone Bergene; Ricanek, Petr; Frigstad, Svein Oskar; Hopstock, Laila Arnesdatter; Opheim, Randi; Kristensen, Vendel Ailin; Høivik, Marte Lie; Carlsen, Monica Hauger; Aas, Anne-Marie (Scandinavian Journal of Gastroenterology;, Peer reviewed; Journal article, 2024)
      Background: Dietary recommendations in inflammatory bowel disease (IBD) are inconclusive, and patients may follow restrictive diets with increased risk of malnutrition. The aim of this study was to compare dietary intakes ...

    • Fatigue in patients with newly diagnosed inflammatory bowel disease: Results from a prospective inception cohort, the IBSEN III study 

      Holten, Kristina Ingeborg; Bernklev, Tomm; Opheim, Randi; Johansen, Ingunn; Olsen, Bjørn Christian Elias Grova; Lund, Charlotte; Strande, Vibeke; Medhus, Asle Wilhelm; Perminow, Gøri Margrete; Bengtson, May-Bente; Boyar Cetinkaya, Raziye; Vatn, Simen Svendsen; Frigstad, Svein Oskar; Aabrekk, Tone Bergene; Detlie, Trond Espen; Hovde, Øistein; Kristensen, Vendel Ailin; Småstuen, Milada Cvancarova; Henriksen, Magne; Huppertz-Hauss, Gert; Høivik, Marte Lie; Jelsness-Jørgensen, Lars-Petter (Peer reviewed; Journal article, 2023)
      Background and aims: Although fatigue is common in inflammatory bowel disease (IBD), its pathogenesis remains unclear. This study aimed to determine the prevalence of fatigue and its associated factors in a cohort of ...

    • Intraoperative distensibility measurement in POEM for achalasia: impact on patient outcome and associations with other outcome variables at 1-year follow-up 

      Evensen, Helge; Sandstad, Olav; Larssen, Lene; Hagen, Milada; Kristensen, Vendel Ailin; Søvik, Torgeir Thorson; Schulz, Anselm; Hauge, Truls; Medhus, Asle Wilhelm (Peer reviewed; Journal article, 2023)
      Background and aims The functional luminal imaging probe (FLIP) can provide measurements of lower esophageal sphincter (LES) distensibility. Studies report that use of intraoperative FLIP examination during peroral ...

    • One year comprehensive prospective follow-up of achalasia patients after peroral endoscopic myotomy 

      Evensen, Helge; Småstuen, Milada Cvancarova; Schulz, Anselm; Kristensen, Vendel Ailin; Larssen, Lene; Skattum, Jorunn Pettersen; Sandstad, Olav; Hauge, Truls; Medhus, Asle Wilhelm (Peer reviewed; Journal article, 2021)
      Peroral endoscopic myotomy (POEM) is an established therapy for achalasia, but outcome evaluation has often been limited to Eckardt score (ES). The present study was aimed to improve knowledge about outcome evaluation and ...

    • Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study 

      Helm, Thea Elisabeth; Høivik, Marte Lie; Anisdahl, Karoline; Buer, Lydia Celine Tansem; Warren, David; Bolstad, Nils; Småstuen, Milada Cvancarova; Moum, Bjørn Allan; Medhus, Asle Wilhelm (Peer reviewed; Journal article, 2024)
      Background: Vedolizumab has since 2021 been available as a subcutaneous formulation. We aimed to assess 18-month drug persistence and possible predictive factors associated with discontinuation, safety, serum drug profile, ...

    • Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring 

      Wiken, Thea H.; Høivik, Marte Lie; Buer, Lydia Celine Tansem; Warren, David J.; Bolstad, Nils; Moum, Bjørn Allan; Anisdahl, Karoline; Småstuen, Milada Cvancarova; Medhus, Asle Wilhelm (Peer reviewed; Journal article, 2023)
      Objective: Vedolizumab (VDZ) for subcutaneous (SC) administration has recently become available. We aimed to assess feasibility, safety and clinical outcome when switching from intravenous (IV) to SC VDZ maintenance ...